Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L)Takashi Seto, Yoichi Nakanishi, Koichi Azuma et al.|Journal of Clinical Oncology|2019Cited by 43
A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).Takashi Seto, Yoichi Nakanishi, Koichi Azuma et al.|Journal of Clinical Oncology|2019Cited by 3
Case of afatinib‐induced severe purpuric drug eruption with gastrointestinal bleedingAoi Oku, Daisuke Tsuruta, Kojiro Tanoue et al.|The Journal of Dermatology|2021Cited by 3